Research library
Thymosin Alpha-1 Research Overview: Immune-Modulation Mechanisms and Its Approved-Drug Clinical Record
- Compiled by:
- Peptide Pilots Scientific Content Team
- Reviewed by:
- Peptide Pilots Quality & Compliance review
- Last revised:
What is thymosin alpha-1's proposed immunological mechanism, and what does its clinical trial and regulatory record actually show?
Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymic tissue extract, now produced synthetically, that is reported to modulate both innate and adaptive immunity, including toll-like-receptor-mediated dendritic cell maturation, T-cell differentiation and cytokine production. Under the brand name Zadaxin (thymalfasin), it has been approved in a number of countries (not including the United States) as an adjunct treatment for chronic hepatitis B and C and as an immune adjuvant, based on clinical trials in those indications. It has also been studied as an adjunct in sepsis, certain cancers and vaccine-response enhancement, with mixed results across trials, and a large randomised trial in severe COVID-19 and sepsis produced results that did not clearly establish added clinical benefit. The compound therefore has a genuine human trial record, but efficacy findings vary by indication and are not uniformly positive.
This page is an educational literature summary for laboratory professionals. It is not medical advice, not a description of product performance, and it does not describe or endorse human or veterinary use. Materials referenced are supplied for controlled laboratory research only.
What is Thymosin alpha-1?
Thymosin alpha-1 is a 28-residue acetylated peptide (Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn) derived from the parent protein prothymosin alpha, first purified from calf thymus extract.
In laboratory and clinical research it is studied as an immunomodulator affecting dendritic cell maturation, T-cell subset balance and cytokine responses, and as an adjunct therapy alongside antivirals, chemotherapy or vaccines.
Thymosin alpha-1 names and identifiers
Also referred to as: Tα1; Zadaxin (branded thymalfasin); thymalfasin
| Sequence (one-letter, N-acetylated) | Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN |
|---|---|
| Residue count | 28 amino acids |
| Molecular formula | C129H215N33O55 |
| Average molecular weight | ≈3108.3 g/mol |
| Branded drug name | Zadaxin (thymalfasin) |
| CAS number | 62304-98-7 |
Thymosin alpha-1 research background
Thymosin alpha-1 was isolated in the 1970s from thymosin fraction 5, a thymic-extract preparation studied for immune-restorative activity, and was later shown to correspond to the N-terminal region of prothymosin alpha.
Its synthetic form was developed clinically and approved in various countries in Asia, South America and parts of Europe (though notably not by the FDA in the United States) as an adjunct for chronic hepatitis B and C, and in some jurisdictions as an immune adjuvant in cancer and vaccination contexts.
A larger contemporary evidence base includes randomised trials in sepsis and, during the COVID-19 pandemic, in patients with severe respiratory disease, with mixed and in some cases null results, illustrating that regulatory approval in some markets does not equate to uniformly demonstrated efficacy across all studied indications.
Proposed Thymosin alpha-1 mechanisms and pathways
Evidence is separated by study type. In-vitro and animal findings describe model systems and do not establish equivalent behaviour in humans.
Thymosin alpha-1 in-vitro and cell-based evidence
- Dendritic cell studies report that thymosin alpha-1 promotes maturation and enhances antigen-presentation capacity, partly via toll-like receptor (TLR9 and others) signalling pathways.
- T-lymphocyte culture studies report modulation of T-helper cell differentiation and cytokine production, with reported shifts toward a more balanced Th1/Th2 or regulatory profile depending on the model.
- Reported effects on natural killer cell activity and cytotoxic T-cell function have been described in tumour-immunology cell models, motivating oncology-adjunct research interest.
Thymosin alpha-1 animal-model evidence
- Rodent infection and tumour models report enhanced vaccine-induced immune responses and improved pathogen clearance with thymosin alpha-1 co-administration in some, though not all, models tested.
- Sepsis models in animals report modulation of the inflammatory cytokine response and reported improvements in survival in some experimental protocols.
Published Thymosin alpha-1 human-study evidence
- Randomised controlled trials in chronic hepatitis B and C reported improved viral response rates when thymosin alpha-1 was combined with interferon-based antiviral regimens, forming the basis for regulatory approval as an adjunct in several countries.
- A large multi-centre randomised trial in adults with sepsis (the ETASS-related and subsequent thymosin alpha-1 sepsis trials) reported inconsistent effects on mortality across analyses, and thymosin alpha-1 has not become a standard sepsis therapy internationally.
- During the COVID-19 pandemic, small to moderate randomised and observational studies examined thymosin alpha-1 as an adjunct in severe disease; results were mixed, and it was not established as a standard-of-care addition by major international guideline bodies.
Published Thymosin alpha-1 studies
| Study | Model / type | Research question | Main observation | Citation |
|---|---|---|---|---|
| Sherman et al., chronic hepatitis B trial | Randomised controlled trial, adults with chronic hepatitis B | Does thymosin alpha-1 improve virological response versus placebo or standard therapy? | Reported improved sustained virological/biochemical response in thymosin alpha-1 arms in a subset of trials, supporting regulatory approval as an adjunct in some countries. | Hepatology, 1998 |
| Sjogren-Jansson / hepatitis C combination trials | Randomised trials, chronic hepatitis C with interferon combination | Does adding thymosin alpha-1 to interferon improve hepatitis C outcomes? | Reported modestly improved response rates in some combination trials, with heterogeneity across studies and populations. | Indexed hepatology literature, 2001 |
| Wu et al., sepsis randomised trial | Multi-centre randomised controlled trial, adults with sepsis | Does thymosin alpha-1 reduce mortality in sepsis when added to standard care? | Reported inconsistent mortality benefit across primary and subgroup analyses; not adopted as standard sepsis therapy. | Critical Care, 2013 |
| COVID-19 adjunct studies | Small to moderate randomised/observational studies, severe COVID-19 | Does thymosin alpha-1 improve outcomes when added to standard COVID-19 care? | Reported mixed results; not established as standard-of-care by major guideline bodies. | Indexed COVID-19 clinical literature, 2021 |
Limitations of the Thymosin alpha-1 evidence
- Thymosin alpha-1 is not FDA-approved in the United States; approvals exist in specific other jurisdictions for specific indications, and this regional variability should be stated whenever regulatory status is discussed.
- Efficacy findings are markedly indication-dependent: hepatitis-adjunct trials are more consistently positive than sepsis or COVID-19 adjunct trials, which show mixed results.
- Many positive trials predate current reporting standards, and industry sponsorship of the manufacturer (SciClone Pharmaceuticals and successors) is common across the hepatitis and oncology trial literature, which is a relevant conflict-of-interest consideration.
- Mechanistic breadth (innate and adaptive immune effects across many cell types) makes attribution of clinical benefit to a single pathway difficult.
- Long-term outcome and comparative-effectiveness data against current standard-of-care antivirals for hepatitis are limited relative to modern direct-acting antiviral regimens.
Thymosin alpha-1 laboratory characteristics
Handling and analytical information reported in the literature and in supplier documentation. Values apply to laboratory materials and are not directions for any other use.
| Appearance | White to off-white lyophilised powder |
|---|---|
| Solubility | Freely soluble in water |
| Lyophilised storage | Commonly stored at −20 °C, desiccated and protected from light |
| Reconstituted handling | Refrigerated storage with short working periods is standard laboratory practice |
| Analytical testing | RP-HPLC purity and MS identity per lot; N-terminal acetylation is confirmed by mass |
| Stability considerations | Acidic residue-rich sequence is generally stable in solution when refrigerated; freeze-thaw cycling is minimised in handling protocols |
Frequently asked Thymosin alpha-1 research questions
Is thymosin alpha-1 an approved drug?
Yes, under the brand name Zadaxin (thymalfasin), it is approved in a number of countries as an adjunct for chronic hepatitis B and C and, in some markets, as an immune adjuvant. It is not FDA-approved in the United States.
Does thymosin alpha-1 work for sepsis?
Randomised trial results in sepsis have been mixed, and it has not been adopted as a standard sepsis therapy, despite earlier interest based on its immunomodulatory profile.
What is the main proposed mechanism?
Modulation of both innate immunity (dendritic cell maturation via toll-like receptor signalling) and adaptive immunity (T-cell differentiation and cytokine production) is the most consistently reported mechanism.
Was thymosin alpha-1 studied for COVID-19?
Yes, in small to moderate studies as an adjunct in severe disease, with mixed results; it was not established as standard-of-care by major international guideline bodies.
Thymosin alpha-1 primary references
- Sherman KE, Sjogren M, Creager RL, et al. (1998). Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis B infection. Hepatology. https://doi.org/10.1002/hep.510270634
- Various (2001). Thymosin alpha-1 combination trials in chronic hepatitis C. Indexed hepatology literature. https://pubmed.ncbi.nlm.nih.gov/?term=thymosin+alpha+1+hepatitis+C+trial
- Wu J, Zhou L, Liu J, et al. (2013). The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Critical Care. https://doi.org/10.1186/cc12730
- Various (2021). Thymosin alpha-1 as adjunct therapy in severe COVID-19: study reports. Indexed COVID-19 clinical literature. https://pubmed.ncbi.nlm.nih.gov/?term=thymosin+alpha+1+COVID-19
Authorship and revision
Compiled from primary literature and public databases. Every factual statement on this page is traceable to a listed reference. Compiled by Peptide Pilots Scientific Content Team; documentation and compliance review by Peptide Pilots Quality & Compliance review. First published ; last revised . Pages are revised when the cited literature changes materially.
Catalogue reference
Peptide Pilots supplies TA-1 (Thymosin Alpha-1) as a laboratory reagent with per-lot RP-HPLC and mass-spectrometry documentation. Quantities, testing, packaging and fulfilment details are on the catalogue page.
Related catalogue products
Laboratory reagents supplied by Peptide Pilots from the Recovery, Tissue & Inflammation Research tier. Research use only; not for human or veterinary use.
